VIVELLE
LOE ApproachingNDATRANSDERMALSYSTEM
Approved
Oct 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
VIVELLE by Novartis is characteristics. Approved for turner syndrome. First approved in 1994.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIVELLE is an estradiol transdermal patch approved in 1994 for Turner Syndrome, a genetic disorder affecting growth and development in females. It delivers estrogen directly through the skin to replace deficient hormone levels and promote normal sexual development and linear growth. The mechanism works by binding to nuclear estrogen receptors, modulating pituitary gonadotropins (LH and FSH) that are elevated in hypogonadal states.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling a smaller, defense-focused brand team rather than growth infrastructure.
Mechanism of Action
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Indications (1)
Worked on VIVELLE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.